Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (381-390 of 455) with videos related to

Pageof 46
Sort By:
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 4, 2020
Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique StudyAndrea Matus González, Talia Gutman, Pamela Lopez-Vargas, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 31, 2021
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label TrialNicola C Edwards, Anna M Price, Samir Mehta, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Clinical Kidney Journal|May 7, 2021
The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trialSharlene A Greenwood, Pelagia Koufaki, Jamie Macdonald, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2020
Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionalsEmma O'Lone, Martin Howell, Andrea K Viecelli, et al.
Pageof 46

Showing results (381-390 of 455) with videos related to

Sort By:
Pageof 46
BMJ Open Diabetes Research & Care|June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose loweringDavid M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Circulation|April 8, 2022
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled TrialsBrendon L Neuen, Megumi Oshima, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 4, 2020
Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique StudyAndrea Matus González, Talia Gutman, Pamela Lopez-Vargas, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE TrialGeorge Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 21, 2021
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trialAjay K Singh, Allison Blackorby, Borut Cizman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 31, 2021
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label TrialNicola C Edwards, Anna M Price, Samir Mehta, et al.
Journal of the American Heart Association|August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE TrialJing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Clinical Kidney Journal|May 7, 2021
The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trialSharlene A Greenwood, Pelagia Koufaki, Jamie Macdonald, et al.
American Journal of Nephrology|December 19, 2017
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline CharacteristicsMeg J Jardine, Kenneth W Mahaffey, Bruce Neal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 11, 2020
Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionalsEmma O'Lone, Martin Howell, Andrea K Viecelli, et al.
Pageof 46